Veeva Systems has released its 2025 MedTech Clinical Benchmark, revealing that medtech clinical teams are increasingly prioritizing collaboration with research sites to reduce manual processes (68%), improve study quality (56%), and gain better oversight (55%). The findings underscore the potential of digital tools to simplify workflows, enhance data exchange, and accelerate study timelines — areas where many companies are still lagging in adoption.

The survey found that on-time data entry, document and data exchange, and compliance monitoring remain major site management challenges. Yet, only 14% of medtechs with revenue above $1 billion — and 24% with revenue below $1 billion — have dedicated site collaboration tools in place. This gap signals an untapped opportunity for technology-driven efficiency gains in clinical trials.

Manual processes remain a notable risk, with 32% citing them as their top hurdle, followed by regulatory compliance (18%) and inspection readiness (18%). Over half of medtech companies (58%) plan to prioritize data collection and cleaning in the coming year, aiming to free up time for high-value trial activities. Meanwhile, AI and machine learning adoption is still in early stages, with 72% of organizations planning infrastructure investments to make their data AI-ready.

According to Kevin Liang, vice president of clinical strategy at Veeva MedTech, the industry is working to connect processes, maintain data integrity, and improve operational efficiency under economic and regulatory pressures — all with the goal of delivering innovations to patients faster.

MedTech Summary

• 68% of medtechs aim to reduce manual processes in site collaboration.

• Only 14–24% currently have site collaboration tools in place.

• 72% plan AI/ML infrastructure investments to improve trial data readiness.